- Area
- Neurology
- Clinical Indication
- Parkinson’s Disease bemdaneprocel (BRT-DA01)
- Cell Type
- Dopaminergic Neuron
Imagine what if?
We believe that cell therapy may have the biggest impact for patients who have diseases where cells die and are not replaced by the body’s natural response.
We have built a pipeline focused on investigating new therapies to treat neurological, cardiovascular, immunological and ophthalmic diseases.
Bluerock pipeline
- Area
- Neurology
- Clinical Indication
- Parkinson’s Disease (BR-DA02)
- Cell Type
- Dopaminergic Neuron
- Area
- Neurology
- Clinical Indication
- Neurodegenerative Disease
- Cell Type
- Microglia
- Area
- Neurology
- Clinical Indication
- Genetic or aquired myelin defects
- Cell Type
- Oligodendrocyte
- Area
- Ophthalmology In partnership with Opsis Therapeutics
- Clinical Indication
- Primary photoreceptor diseases (OpCT-001)
- Cell Type
- Photoreceptor
- Area
- Ophthalmology In partnership with Opsis Therapeutics
- Clinical Indication
- Early / Intermediate Dry AMD
- Cell Type
- Retinal Pigment Epithelium (RPE)
- Area
- Ophthalmology In partnership with Opsis Therapeutics
- Clinical Indication
- Late Dry AMD / GA
- Cell Type
- Photoreceptor + RPE
- Area
- Cardiology
- Clinical Indication
- Heart Failure (BR-CM01)
- Cell Type
- Cardiomyocyte
- Area
- Immunology In partnership with bit.bio
- Clinical Indication
- Autoimmune Disease
- Cell Type
- CD4+ T-Reg
